SCM Lifescience

BG Rhee, Ph.D., President and CEO

Seoul, Korea

(KOSDAQ: 2908060)

Virtual Presentation

SCM Lifescience is developing allogeneic high purity clonal mesenchymal stem cells for immune related diseases. Three projects that are currently in the Phase II clinical stage deal with moderate to severe atopic dermatitis, chronic GvHD, and moderate to severe acute pancreatitis. SCM is looking for local partners for co-development of these projects in the U.S., EU, and Asia.

By using this website you agree to accept our Privacy Policy and Terms & Conditions